Cytomx Therapeutics Stock Earnings Reports

CytomX highlighted strong clinical and financial progress in Q1 2026 centered on Varseta-M, its first-in-class EpCAM-targeting antibody drug conjugate enabled by the PROBODY masking platform. Clinical: Varseta-M has shown encouraging Phase I activity in late-line metastatic colorectal cancer (CRC) with a confirmed overall response rate (ORR) between ~20%–32% and ~7 months median progression-free survival (PFS). Enrollment across the Phase I program is now 113 patients, including completed dose-optimization cohorts (40 patients total) at 8.6 and 10 mg/kg (adjusted ideal body weight). The company expects a comprehensive Phase I update (safety and efficacy, including PFS and an initial look at OS) in the second half of 2026 and aims to select a registrational dose and advance into a pivotal/registrational study in late-line CRC in H1 2027. Safety: diarrhea (principal AE) management strategies (prophylactic loperamide and budesonide and adjusted dosing) have reduced early high-grade events in optimization cohorts and the goal is to manage Grade 3 rates into a ~10%–20% range. Development plan: parallel efforts to move Varseta-M into combinations — bevacizumab combo (data expected by H1 2027) and a chemotherapy combination (Phase I/II start planned H2 2026) — and to open Phase I expansion cohorts in other EpCAM-expressing tumors in H2 2026 with a view to pan-tumor potential. CX-801 (masked interferon alpha-2b) is advancing in Phase I for PD-1–refractory melanoma; monotherapy escalation has exceeded the approved dose of unmasked IFN alpha-2b and combination escalation with pembrolizumab is enrolling; initial CX-801 data expected by year-end. Financials: cash, cash equivalents and investments were $346.7M as of March 31, 2026, and management projects runway to at least H2 2028 (guidance excludes future collaboration milestones); Q1 revenue declined versus prior year due to completion of collaboration obligations; R&D and G&A spending is increasing modestly as development and manufacturing scale for Varseta-M. Management intends to prioritize capital allocation around Varseta-M and the PROBODY platform.